CVM News and Press, Cel-Sci Corporation From 07/17/23

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the under...

2023-07-14 10:34:58 ET CEL-SCI Corporation ( NYSE: CVM ) lost ~7% in early trading on on Friday after the company announced the outcome of a recent meeting with the FDA regarding Multikine, an immunotherapy targeted at newly diagnosed squamous cell carcinoma of the head and neck (SC...

FDA acknowledges the great need for improved treatments for head and neck cancer, particularly the locally advanced oral cavity that CEL-SCI is targeting and is open to a close collaboration with CEL-SCI to help demonstrate that Multikine could be such a therapy Approval is being purs...

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of patients with a higher level of tumor cell PD-L1 expression Combination ...

CEL-SCI Corporation (NYSE American: CVM) today announced it will present the new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN), at the American Head and Neck Cancer Societyȁ...

Histopathology analysis confirmed improved 5-year survival in Multikine-treated subjects, showed improved progression free survival and improved local regional control, and significantly lowered death rate compared to control subjects who received standard of care alone CEL-SCI Corp...

2023-05-12 16:58:59 ET Cel-Sci press release ( NYSE: CVM ): Q2 GAAP EPS of -$0.19 misses by $0.02 . CEL-SCI had $10 million in cash and cash equivalents on March 31, 2023. For further details see: Cel-Sci GAAP EPS of -$0.19 misses by $0.02

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2023, as well as key clinical and corporate developments. Clinical and Corporate Developments include: In addition to pursuing approval by the US Food and Drug Administration (F...

2023-04-28 08:33:44 ET Hillstream BioPharma ( HILS ) -57% on pricing $2.65M equity offering . Centogene ( CNTG ) -26% receives Nasdaq non-compliance notice . Cloudflare ( NET ) -25% after Q1 earnings release . Snap ( SNAP ) -18% afte...

2023-04-28 04:52:47 ET Phase 3 cancer immunotherapy company, CEL-SCI ( NYSE: CVM ) prices an underwritten confidentially marketed public offering of 794,117 shares at an offering price of $1.70 per share. The closing of the offering is expected to take place on or about May 2,...